证券代码：000950 证券简称：重药控股 公告编号：2026-008 重药控股股份有限公司 第九届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 重药控股股份有限公司（以下简称"公司"）第九届董事会第二十二次会议于 2026年3月10日在公司会议室以现场与通讯表决相结合的形式召开，会议通知于 2026年2月28日以电子邮件方式发出。会议应出席董事11人，实际出席会议的董 事11人。会议由公司董事长袁泉主持。本次会议的召开符合《公司法》《公司章 程》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于2026年度融资计划的议案》 具体内容详见同日披露的《关于2026年度融资计划的公告》。 表决结果：同意11票，反对0票，弃权0票。 本议案尚需提交股东会审议。 （二）审议通过《关于 2026 年度重药控股下属子公司融资计划的议案》 具体内容详见同日披露的《关于2026年度重药控股下属子公司融资计划的公 告》。 表决结果：同意11票，反对0票，弃权0票。 本议案尚需提交股东会审议。 （三）审议通过《关于控 ...

证券代码：000950 证券简称：重药控股 公告编号：2026-007 重药控股股份有限公司 关于回购股份进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 2.公司以集中竞价交易方式回购股份符合下列要求： 重药控股股份有限公司（以下简称"公司"）分别于 2025 年 7 月 10 日、2025 年 7 月 28 日召开第九届董事会第十五次会议、2025 年第三次临时股东会，审议 通过了《关于回购公司股份的议案》，同意公司使用自有资金及股票回购专项贷 款，通过深圳证券交易所交易系统以集中竞价交易方式回购公司已发行的人民币 普通股（A 股），用于减少公司注册资本。本次用于回购股份的资金总额不低于 人民币 8,000 万元（含本数），不超过人民币 10,000 万元（含本数），回购价格 不超过人民币 6.6 元/股（含本数），回购期限为自股东会审议通过回购股份事项 之日起 12 个月内。具体内容详见公司在巨潮资讯网（www.cninfo.com.cn）披露 的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份 ...

Company Developments - The company has made progress in its operations and external collaborations, including a milestone payment from Pfizer [1] - A subsidiary, Yaoyou Pharmaceutical, has signed a global exclusive licensing agreement with Pfizer, receiving an initial payment of $150 million in January 2026, with an additional $500 million in milestone payments to follow [2] - The company continues to execute its share repurchase plan, having repurchased a total of 80.99 million yuan by December 2025, and is optimizing its asset-liability ratio through the transfer of financial company equity [3] Industry Policy and Environment - The pharmaceutical commercial sector is influenced by the innovative drug concept and policy expectations, with foreign capital net purchases and sector activity observed in December 2025, which may have a subsequent impact on the company's stock price [4]

Group 1 - The Chongqing state-owned enterprise reform sector increased by 0.61% compared to the previous trading day, with Qianli Technology leading the gains [1] - On the same day, the Shanghai Composite Index closed at 4131.98, up 0.09%, while the Shenzhen Component Index closed at 14160.93, down 0.35% [1] - The trading volume and turnover for Qianli Technology were 347,300 shares and 369 million yuan, respectively, with a price increase of 2.22% [1] Group 2 - The net outflow of main funds in the Chongqing state-owned enterprise reform sector was 2.3995 million yuan, while retail investors saw a net inflow of 4.728 million yuan [2] - The trading data indicates that Qianli Technology had a net inflow of 25.4663 million yuan from main funds, while retail investors had a net outflow of 1.3324 million yuan [3] - The overall performance of stocks in the sector showed mixed results, with some stocks like Qianli Technology and Sanfeng Environment experiencing gains, while others like Chongqing Port and Chongqing Water experienced losses [3]

Market Overview - The Chongqing state-owned enterprise reform sector declined by 0.7% compared to the previous trading day, with Chongqing Pharmaceutical Holdings leading the decline [1] - The Shanghai Composite Index closed at 4128.37, up 0.13%, while the Shenzhen Component Index closed at 14210.63, up 0.02% [1] Stock Performance - Notable stock performances include: - Shanghai Sanmao (600689) closed at 14.29, up 0.78% with a trading volume of 30,300 shares and a turnover of 43.27 million yuan - Chongqing Construction (600939) closed at 3.23, up 0.31% with a trading volume of 133,800 shares and a turnover of 43.05 million yuan - Chongqing Pharmaceutical Holdings (000950) closed at 5.90, down 1.83% with a trading volume of 366,700 shares and a turnover of 218 million yuan [1][2] Capital Flow - The Chongqing state-owned enterprise reform sector experienced a net outflow of 119 million yuan from institutional investors, while retail investors saw a net inflow of 62.65 million yuan [2] - The capital flow for individual stocks shows: - Jieling Pickled Vegetables (002507) had a net inflow of 5.71 million yuan from institutional investors, but a net outflow of 13.01 million yuan from retail investors [3] - Chongqing Water (601158) had a net outflow of 3.40 million yuan from institutional investors, with a net inflow of 1.18 million yuan from retail investors [3]

Core Viewpoint - A major pharmaceutical company, Zhongyao Holdings, has come under scrutiny due to tax issues, with a total of 76.2 million yuan in tax payments required over two instances, raising concerns about its internal control and compliance capabilities [1][2]. Tax Compliance Concerns - The tax payments relate to the "Western Development Corporate Income Tax Incentive Policy," which allows a reduced tax rate of 15% for qualifying businesses, but requires that 60% of revenue comes from encouraged industries [2]. - The repeated tax payments suggest potential systemic issues in the company's judgment regarding the applicability of tax incentives, indicating possible inconsistencies in understanding the policy among subsidiaries [2]. Financial Impact and Cash Flow Pressure - While the tax payment amount may not significantly impact the overall performance of the group, which has annual revenues exceeding 80 billion yuan, the associated financial risks are notable [3]. - The late payment penalties, which accrue at a daily rate of 0.05% (approximately 18.25% annually), highlight a disconnect between financial planning and tax compliance, suggesting that the company may not have adequately reserved funds for tax liabilities [3]. Governance Structure and Internal Control Issues - Zhongyao Holdings operates under a dual-entity structure, which may lead to uneven control over subsidiaries and potential management challenges [4]. - The involvement of 29 subsidiaries in tax issues indicates that these risks are not isolated incidents, raising questions about the adequacy of guidance provided to subsidiaries regarding local tax regulations [4]. Conclusion - The ongoing tax payment issues at Zhongyao Holdings serve as a warning to all companies benefiting from regional tax incentives, emphasizing the need for rigorous compliance and management of tax-related matters [5]. - The market will be closely watching whether the company will conduct further tax self-assessments or adjust its business strategies in the western regions [5].

Group 1 - Company X is currently undergoing auditing and evaluation work [1] - Company Y has not yet received any orders in the "space photovoltaic" sector [1] - Company Z plans to invest 1 billion yuan in the construction of a synthetic biology manufacturing project in Xinjiang [1] Group 2 - Company A has won a 994 million yuan EPC project [1] - Company B's subsidiary has secured a project worth 101 million yuan [1] - Company C's subsidiary is expected to be awarded a project for the total engineering contract of Huahong FAB9B [1] Group 3 - Company D reported a net profit of 177 million yuan for 2025, representing a year-on-year increase of 42.81% [1] - Company E reported a net profit of 34.93 million yuan for 2025, with a year-on-year growth of 30.13% [1] Group 4 - Company F plans to acquire a portion of equity in Company G, which will increase its holding and achieve control [1] - Company H and its subsidiary plan to transfer 80% of the equity in Wuhan Shengchong [1] Group 5 - Company I has completed the repurchase of 875,000 shares [2] - Company J plans to raise no more than 5 billion yuan through a private placement for a 20GWh power battery project [2] - Company K's actual controller is under investigation by the China Securities Regulatory Commission for alleged market manipulation [2]

Group 1 - The company, Chongqing Pharmaceutical Holdings, announced that as of January 31, 2026, it has repurchased a total of 15,406,600 shares through a dedicated securities account via centralized bidding, which represents approximately 0.8915% of the company's total share capital [2]

Group 1 - The core point of the article is that Chongqing Pharmaceutical Holdings (重药控股) has repurchased a total of 15.4066 million shares, accounting for approximately 0.8915% of the company's total share capital, as part of its share buyback program [1] - The highest transaction price during the buyback was 5.48 yuan per share, while the lowest was 5.01 yuan per share [1] - The total amount paid for the share repurchase was 80.9988 million yuan, excluding transaction fees [1] Group 2 - The buyback is in compliance with relevant laws, regulations, and the company's share repurchase plan requirements [1]

Core Viewpoint - The company has announced a share buyback plan using its own funds and special loans, with a total buyback amount ranging from 80 million to 100 million yuan, at a price not exceeding 6.6 yuan per share, over a period of 12 months [1] Summary by Relevant Sections - **Share Buyback Details** - The company plans to repurchase shares to reduce capital, with a total buyback fund of 80 million to 100 million yuan [1] - The buyback price is capped at 6.6 yuan per share [1] - The buyback period is set for 12 months [1] - **Current Buyback Status** - As of January 31, 2026, the company has repurchased a total of 15.4066 million shares, accounting for approximately 0.8915% of the total share capital [1] - The highest transaction price recorded was 5.48 yuan per share, while the lowest was 5.01 yuan per share [1] - The total amount paid for the buyback so far is approximately 80.9988 million yuan [1] - **Future Plans** - The company will continue to implement the buyback plan as per regulations and will disclose further information accordingly [1]